{"title": "Dhir V, Singla M, Gupta N, Goyal P, Sagar V, Sharma A, et al. Randomized controlled trial comparing 2 different starting doses of methotrexate in rheumatoid arthritis. Clinical Therapeutics. 2014;36(7):1005.", "paper_uid": "8113db3a", "reference": "Dhir V, Singla M, Gupta N, Goyal P, Sagar V, Sharma A, et al. Randomized controlled trial comparing 2 different starting doses of methotrexate in rheumatoid arthritis. Clinical Therapeutics. 2014;36(7):1005.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "10", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "24976447"}
{"title": "Mueller RBea. Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. Journal of Clinical Medicine. 2019;8.", "paper_uid": "6e1cd0bc", "reference": "Mueller RBea. Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. Journal of Clinical Medicine. 2019;8.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "12a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "30832414"}
{"title": "Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263.", "paper_uid": "2671be0a", "reference": "Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "12a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "15262104"}
{"title": "Pope JE, Haraoui B, Rampakakis E, Psaradellis E, Thorne C, Sampalis JS. Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial. Arthritis care & research. 2013;65(9):1401.", "paper_uid": "06522c73", "reference": "Pope JE, Haraoui B, Rampakakis E, Psaradellis E, Thorne C, Sampalis JS. Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial. Arthritis care & research. 2013;65(9):1401.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "12a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "23509040"}
{"title": "Verstappen SM, Jacobs JW, Veen MJVD, Heurkens AH, Schenk Y, Borg EJt, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Annals of the Rheumatic Diseases. 2007;66(11):1443.", "paper_uid": "41ed8200", "reference": "Verstappen SM, Jacobs JW, Veen MJVD, Heurkens AH, Schenk Y, Borg EJt, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Annals of the Rheumatic Diseases. 2007;66(11):1443.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "12a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "17519278"}
{"title": "Fransen J. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis BMJ. 2005; 64:1294–1298.", "paper_uid": "c1d5b421", "reference": "Fransen J. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis BMJ. 2005; 64:1294–1298.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "12a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "15829574"}
{"title": "Verstappen SMB, M. F.; et. al. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. Ann Rheum Dis BMJ. 2010;69(6):1044-8.", "paper_uid": "4b539132", "reference": "Verstappen SMB, M. F.; et. al. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. Ann Rheum Dis BMJ. 2010;69(6):1044-8.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "12a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "19581281"}
{"title": "Akdemir G. Comparison between low disease activity or das remission as treatment target in patients with early active rheumatoid arthritis. RMD Open. 2018;4(1).", "paper_uid": "79161999", "reference": "Akdemir G. Comparison between low disease activity or das remission as treatment target in patients with early active rheumatoid arthritis. RMD Open. 2018;4(1).", "study_design": "Observational Study", "PICO_IDX": "13", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "29862045"}
{"title": "Dhir V. Comparison of two different folic acid doses with methotrexate - a randomized controlled trial (FOLVARI Study). Arthritis Research & Therapy. 2015;17:156.", "paper_uid": "a6672bfe", "reference": "Dhir V. Comparison of two different folic acid doses with methotrexate - a randomized controlled trial (FOLVARI Study). Arthritis Research & Therapy. 2015;17:156.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "15", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "26063325"}
{"title": "Morgan Sea. Supplementation with Folic Acid during Methotrexate Therapy for Rheumatoid Arthritis. Ann Intern Med. 1994;121:833-41.", "paper_uid": "bdf72d22", "reference": "Morgan Sea. Supplementation with Folic Acid during Methotrexate Therapy for Rheumatoid Arthritis. Ann Intern Med. 1994;121:833-41.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "15", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "7978695"}
{"title": "Islam MS, Haq SA, Islam MN, Azad AK, Islam MA, Barua. Comparative efficacy of subcutaneous versus oral methotrexate in active rheumatoid arthritis. Mymensingh Medical Journal: MMJ. 2013;22(3):483.", "paper_uid": "dd941abe", "reference": "Islam MS, Haq SA, Islam MN, Azad AK, Islam MA, Barua. Comparative efficacy of subcutaneous versus oral methotrexate in active rheumatoid arthritis. Mymensingh Medical Journal: MMJ. 2013;22(3):483.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "18", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "23982537"}
{"title": "O' Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. New England Journal of Medicine. 2013;369(4):307.", "paper_uid": "a55c0534", "reference": "O' Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. New England Journal of Medicine. 2013;369(4):307.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "19", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "23755969"}
{"title": "Lopez-Olivo MAT, J.H; Martinez-Lopez, J.A.; Pollono, E.N.; Cueto, J.P.; Gonzales-Crespo, M.R.; Fulton, S.; Suarez-Almazor, M.E. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898.", "paper_uid": "45b0286b", "reference": "Lopez-Olivo MAT, J.H; Martinez-Lopez, J.A.; Pollono, E.N.; Cueto, J.P.; Gonzales-Crespo, M.R.; Fulton, S.; Suarez-Almazor, M.E. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "19", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "22948700"}
{"title": "Dougados M. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases. 1999;58(4):220.", "paper_uid": "fd4777bd", "reference": "Dougados M. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases. 1999;58(4):220.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "1a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "10364900"}
{"title": "Haagsma C, van Riel P, de Jong A, van de Putte L. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology. 1997;36(10):1082.", "paper_uid": "d7a31839", "reference": "Haagsma C, van Riel P, de Jong A, van de Putte L. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology. 1997;36(10):1082.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "1a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "9374925"}
{"title": "Zeb S. Comparison of short-term efficacy of leflunomide and methotrexate in active rheumatoid arthritis. Journal of Postgraduate Medical Institute. 2016;30(2):177.", "paper_uid": "fa180e46", "reference": "Zeb S. Comparison of short-term efficacy of leflunomide and methotrexate in active rheumatoid arthritis. Journal of Postgraduate Medical Institute. 2016;30(2):177.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "1a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": null}
{"title": "Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine. 1999;159(21):2542.", "paper_uid": "ade90865", "reference": "Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine. 1999;159(21):2542.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "1b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "10573044"}
{"title": "Fiehn C, Jacki S, Heilig B, Lampe M, Wiesmullerr G, Richter C, et al. Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone. Rheumatology International. 2007;27(10):975.", "paper_uid": "ad9d3d6b", "reference": "Fiehn C, Jacki S, Heilig B, Lampe M, Wiesmullerr G, Richter C, et al. Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone. Rheumatology International. 2007;27(10):975.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "1b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "17429636"}
{"title": "O' Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. New England Journal of Medicine. 2013;369(4):307.", "paper_uid": "a55c0534", "reference": "O' Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. New England Journal of Medicine. 2013;369(4):307.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "20", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "23755969"}
{"title": "Lopez-Olivo MAT, J.H; Martinez-Lopez, J.A.; Pollono, E.N.; Cueto, J.P.; Gonzales-Crespo, M.R.; Fulton, S.; Suarez-Almazor, M.E. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898.", "paper_uid": "45b0286b", "reference": "Lopez-Olivo MAT, J.H; Martinez-Lopez, J.A.; Pollono, E.N.; Cueto, J.P.; Gonzales-Crespo, M.R.; Fulton, S.; Suarez-Almazor, M.E. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "20", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "22948700"}
{"title": "Fleischmann R. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. The Lancet. 2017;390(10093):457.", "paper_uid": "f8f1a82c", "reference": "Fleischmann R. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. The Lancet. 2017;390(10093):457.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "21a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "28629665"}
{"title": "Kaneko Y AT, Tanaka Y, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). BMJ. 2016;75:1917-23.", "paper_uid": "323b4f71", "reference": "Kaneko Y AT, Tanaka Y, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). BMJ. 2016;75:1917-23.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "21a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "26733110"}
{"title": "Dougados M. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Annals of the Rheumatic Diseases. 2014;73(5):803.", "paper_uid": "d76da5a9", "reference": "Dougados M. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Annals of the Rheumatic Diseases. 2014;73(5):803.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "21a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "24473673"}
{"title": "Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. Annals of the Rheumatic Diseases. 2009;68(7):1146.", "paper_uid": "39e9c906", "reference": "Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. Annals of the Rheumatic Diseases. 2009;68(7):1146.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "21a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "18794178"}
{"title": "Capell HA. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Annals of the Rheumatic Diseases. 2007;66(2):235.", "paper_uid": "8f68ef49", "reference": "Capell HA. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Annals of the Rheumatic Diseases. 2007;66(2):235.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "21a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "16926184"}
{"title": "Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.[Erratum appears in Arthritis Rheum. 2008 Mar;58(3):887]. Arthritis & Rheumatism. 2006;54(9):2817.", "paper_uid": "d40d9e70", "reference": "Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.[Erratum appears in Arthritis Rheum. 2008 Mar;58(3):887]. Arthritis & Rheumatism. 2006;54(9):2817.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "21a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "16947782"}
{"title": "van Riel PL. Efficacy and safely of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: The ADORE study. Annals of the Rheumatic Diseases. 2006;65(11):1478.", "paper_uid": "bcdcb109", "reference": "van Riel PL. Efficacy and safely of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: The ADORE study. Annals of the Rheumatic Diseases. 2006;65(11):1478.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "21a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "16464988"}
{"title": "Dougados M, Emery P, Lemmel EM, Zerbini CA, Brin S, Riel PV. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? Annals of the Rheumatic Diseases. 2005;64(1):44.", "paper_uid": "49208898", "reference": "Dougados M, Emery P, Lemmel EM, Zerbini CA, Brin S, Riel PV. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? Annals of the Rheumatic Diseases. 2005;64(1):44.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "21a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "15271770"}
{"title": "Edwards JC. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. New England Journal of Medicine. 2004;350(25):2572.", "paper_uid": "71272a3e", "reference": "Edwards JC. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. New England Journal of Medicine. 2004;350(25):2572.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "21a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "15201414"}
{"title": "van Riel PL. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: The ADORE trial. Annals of the Rheumatic Diseases. 2008;67(8):1104.", "paper_uid": "cdb4d7a1", "reference": "van Riel PL. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: The ADORE trial. Annals of the Rheumatic Diseases. 2008;67(8):1104.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "21a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "17666447"}
{"title": "Strand V, et al. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. RMD Open. 2019;5.", "paper_uid": "83353996", "reference": "Strand V, et al. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. RMD Open. 2019;5.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "21a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "31673419"}
{"title": "Breedveld FA, S.; Yin, M.; et. al. Rituximab Pharmacokinetics in Patients With Rheumatoid Arthritis: B-Cell Levels Do Not Correlate With Clinical Response. J Clin Pharmacol. 2007;47:1119-28.", "paper_uid": "ce4b2bdc", "reference": "Breedveld FA, S.; Yin, M.; et. al. Rituximab Pharmacokinetics in Patients With Rheumatoid Arthritis: B-Cell Levels Do Not Correlate With Clinical Response. J Clin Pharmacol. 2007;47:1119-28.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "21a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "17766699"}
{"title": "Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis & Rheumatism. 1998;41(9):1552.", "paper_uid": "553e309f", "reference": "Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis & Rheumatism. 1998;41(9):1552.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "21a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "9751087"}
{"title": "Brown S, Everett CC, Naraghi. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. Health Technology Assessment (Winchester, England). 2018;22(34):1.", "paper_uid": "b6823603", "reference": "Brown S, Everett CC, Naraghi. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. Health Technology Assessment (Winchester, England). 2018;22(34):1.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "24", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "29900829"}
{"title": "Manders SH, et al. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. BioMed Central. 2015;17.", "paper_uid": "fba7b4bd", "reference": "Manders SH, et al. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. BioMed Central. 2015;17.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "24", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "25997746"}
{"title": "Brown S, Everett CC, Naraghi. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. Health Technology Assessment (Winchester, England). 2018;22(34):1.", "paper_uid": "b6823603", "reference": "Brown S, Everett CC, Naraghi. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. Health Technology Assessment (Winchester, England). 2018;22(34):1.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "24", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "29900829"}
{"title": "Manders SH, et al. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. BioMed Central. 2015;17.", "paper_uid": "fba7b4bd", "reference": "Manders SH, et al. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. BioMed Central. 2015;17.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "24", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "25997746"}
{"title": "Santos-Faria D. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor (TNFi) in rheumatoid arthritis patients who discontinued a first TNFi. ÓRGÃO OfICIAL dA SOCIEdAdE PORTUGUESA dE REUMATOLOGIA. 2019;44:103-13.", "paper_uid": "05c073e4", "reference": "Santos-Faria D. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor (TNFi) in rheumatoid arthritis patients who discontinued a first TNFi. ÓRGÃO OfICIAL dA SOCIEdAdE PORTUGUESA dE REUMATOLOGIA. 2019;44:103-13.", "study_design": "Observational Study", "PICO_IDX": "24", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "31243259"}
{"title": "Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Annals of the Rheumatic Diseases. 2007;66(7):893.", "paper_uid": "ca0be03a", "reference": "Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Annals of the Rheumatic Diseases. 2007;66(7):893.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "24", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "17412737"}
{"title": "Tarp S, Furst DE, Boers M, Luta G, Bliddal H, Tarp U, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. [Review]. Rheumatology. 2017;56(3):417.", "paper_uid": "a1e03f7a", "reference": "Tarp S, Furst DE, Boers M, Luta G, Bliddal H, Tarp U, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. [Review]. Rheumatology. 2017;56(3):417.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "24", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "28013201"}
{"title": "Singh JA WG, Christensen R, Tanjong Ghogomu E, Maxwell LJ, MacDonald JK, Filippini G, Skoetz N, Francis DK, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Cameron C, Lunn MPT, Tugwell P, Buchbinder R. Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review). Cochrane Library. 2016(4).", "paper_uid": "21011e18", "reference": "Singh JA WG, Christensen R, Tanjong Ghogomu E, Maxwell LJ, MacDonald JK, Filippini G, Skoetz N, Francis DK, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Cameron C, Lunn MPT, Tugwell P, Buchbinder R. Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review). Cochrane Library. 2016(4).", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "24", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "21328309"}
{"title": "Brown S, Everett CC, Naraghi. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. Health Technology Assessment (Winchester, England). 2018;22(34):1.", "paper_uid": "b6823603", "reference": "Brown S, Everett CC, Naraghi. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. Health Technology Assessment (Winchester, England). 2018;22(34):1.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "25", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "29900829"}
{"title": "Manders SH, et al. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. BioMed Central. 2015;17.", "paper_uid": "fba7b4bd", "reference": "Manders SH, et al. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. BioMed Central. 2015;17.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "25", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "25997746"}
{"title": "Tarp S, Furst DE, Boers M, Luta G, Bliddal H, Tarp U, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. [Review]. Rheumatology. 2017;56(3):417.", "paper_uid": "a1e03f7a", "reference": "Tarp S, Furst DE, Boers M, Luta G, Bliddal H, Tarp U, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. [Review]. Rheumatology. 2017;56(3):417.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "25", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "28013201"}
{"title": "BLOMley MJ. Effectiveness of a Third Tumor Necrosis Factor-a-blocking Agent Compared with Rituximab After Failure of 2 TNF-blocking Agents in Rheumatoid Arthritis. The Journal of Rheumatology. 2017;38(11):2355-61.", "paper_uid": "5f4ff353", "reference": "BLOMley MJ. Effectiveness of a Third Tumor Necrosis Factor-a-blocking Agent Compared with Rituximab After Failure of 2 TNF-blocking Agents in Rheumatoid Arthritis. The Journal of Rheumatology. 2017;38(11):2355-61.", "study_design": "Observational Study", "PICO_IDX": "25", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "21885487"}
{"title": "Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Annals of the Rheumatic Diseases. 2007;66(7):893.", "paper_uid": "ca0be03a", "reference": "Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Annals of the Rheumatic Diseases. 2007;66(7):893.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "25", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "17412737"}
{"title": "Tarp S, Furst DE, Boers M, Luta G, Bliddal H, Tarp U, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. [Review]. Rheumatology. 2017;56(3):417.", "paper_uid": "a1e03f7a", "reference": "Tarp S, Furst DE, Boers M, Luta G, Bliddal H, Tarp U, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. [Review]. Rheumatology. 2017;56(3):417.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "25", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "28013201"}
{"title": "Singh JA WG, Christensen R, Tanjong Ghogomu E, Maxwell LJ, MacDonald JK, Filippini G, Skoetz N, Francis DK, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Cameron C, Lunn MPT, Tugwell P, Buchbinder R. Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review). Cochrane Library. 2016(4).", "paper_uid": "21011e18", "reference": "Singh JA WG, Christensen R, Tanjong Ghogomu E, Maxwell LJ, MacDonald JK, Filippini G, Skoetz N, Francis DK, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Cameron C, Lunn MPT, Tugwell P, Buchbinder R. Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review). Cochrane Library. 2016(4).", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "25", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "21328309"}
{"title": "Menon Nea. Comparison of Intra-articular Glucocorticoid Injections with DMARDs versus DMARDs alone in Rheumatoid Arthritis. Journal of the association of physicians of india. 2014;62:673-6.", "paper_uid": "5c2f0c43", "reference": "Menon Nea. Comparison of Intra-articular Glucocorticoid Injections with DMARDs versus DMARDs alone in Rheumatoid Arthritis. Journal of the association of physicians of india. 2014;62:673-6.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "28", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "25856933"}
{"title": "Dougados M. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases. 1999;58(4):220.", "paper_uid": "fd4777bd", "reference": "Dougados M. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases. 1999;58(4):220.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "2a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "10364900"}
{"title": "Haagsma C, van Riel P, de Jong A, van de Putte L. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology. 1997;36(10):1082.", "paper_uid": "d7a31839", "reference": "Haagsma C, van Riel P, de Jong A, van de Putte L. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology. 1997;36(10):1082.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "2a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "9374925"}
{"title": "Dougados M. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases. 1999;58(4):220.", "paper_uid": "fd4777bd", "reference": "Dougados M. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases. 1999;58(4):220.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "2a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "10364900"}
{"title": "Zeb S. Comparison of short-term efficacy of leflunomide and methotrexate in active rheumatoid arthritis. Journal of Postgraduate Medical Institute. 2016;30(2):177.", "paper_uid": "fa180e46", "reference": "Zeb S. Comparison of short-term efficacy of leflunomide and methotrexate in active rheumatoid arthritis. Journal of Postgraduate Medical Institute. 2016;30(2):177.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "2a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": null}
{"title": "Dougados M. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases. 1999;58(4):220.", "paper_uid": "fd4777bd", "reference": "Dougados M. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases. 1999;58(4):220.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "2b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "10364900"}
{"title": "Haagsma C, van Riel P, de Jong A, van de Putte L. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology. 1997;36(10):1082.", "paper_uid": "d7a31839", "reference": "Haagsma C, van Riel P, de Jong A, van de Putte L. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology. 1997;36(10):1082.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "2b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "9374925"}
{"title": "Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine. 1999;159(21):2542.", "paper_uid": "ade90865", "reference": "Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine. 1999;159(21):2542.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "2b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "10573044"}
{"title": "Fiehn C, Jacki S, Heilig B, Lampe M, Wiesmullerr G, Richter C, et al. Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone. Rheumatology International. 2007;27(10):975.", "paper_uid": "ad9d3d6b", "reference": "Fiehn C, Jacki S, Heilig B, Lampe M, Wiesmullerr G, Richter C, et al. Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone. Rheumatology International. 2007;27(10):975.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "2b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "17429636"}
{"title": "Dougados M. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases. 1999;58(4):220.", "paper_uid": "fd4777bd", "reference": "Dougados M. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases. 1999;58(4):220.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "3a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "10364900"}
{"title": "Haagsma C, van Riel P, de Jong A, van de Putte L. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology. 1997;36(10):1082.", "paper_uid": "d7a31839", "reference": "Haagsma C, van Riel P, de Jong A, van de Putte L. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology. 1997;36(10):1082.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "3a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "9374925"}
{"title": "de Jong PHP, Hazes JM, Barendregt PJ, Huisman M, van Zeben D, van der Lubbe PA, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Annals of the Rheumatic Diseases. 2013;72(1):72.", "paper_uid": "ca2ae2ab", "reference": "de Jong PHP, Hazes JM, Barendregt PJ, Huisman M, van Zeben D, van der Lubbe PA, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Annals of the Rheumatic Diseases. 2013;72(1):72.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "3a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "22679301"}
{"title": "Moreland LW, Zhang J. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The treatment of early aggressive rheumatoid arthritis trial. Arthritis and Rheumatism. 2012;64(9):2824.", "paper_uid": "ccd87125", "reference": "Moreland LW, Zhang J. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The treatment of early aggressive rheumatoid arthritis trial. Arthritis and Rheumatism. 2012;64(9):2824.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "3b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "22508468"}
{"title": "Dougados M. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases. 1999;58(4):220.", "paper_uid": "fd4777bd", "reference": "Dougados M. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases. 1999;58(4):220.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "4a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "10364900"}
{"title": "Haagsma C, van Riel P, de Jong A, van de Putte L. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology. 1997;36(10):1082.", "paper_uid": "d7a31839", "reference": "Haagsma C, van Riel P, de Jong A, van de Putte L. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology. 1997;36(10):1082.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "4a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "9374925"}
{"title": "de Jong PHP. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: First results of the tREACH trial. Annals of the Rheumatic Diseases. 2013;72(1):72.", "paper_uid": "1f1358a6", "reference": "de Jong PHP. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: First results of the tREACH trial. Annals of the Rheumatic Diseases. 2013;72(1):72.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "4a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "22679301"}
{"title": "Dougados M. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases. 1999;58(4):220.", "paper_uid": "fd4777bd", "reference": "Dougados M. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases. 1999;58(4):220.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "4b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "10364900"}
{"title": "Haagsma C. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology. 1997;36(10):1082.", "paper_uid": "26ed4e54", "reference": "Haagsma C. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology. 1997;36(10):1082.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "4b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "9374925"}
{"title": "Moreland LW, Zhang J. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The treatment of early aggressive rheumatoid arthritis trial. Arthritis and Rheumatism. 2012;64(9):2824.", "paper_uid": "ccd87125", "reference": "Moreland LW, Zhang J. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The treatment of early aggressive rheumatoid arthritis trial. Arthritis and Rheumatism. 2012;64(9):2824.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "4b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "22508468"}
{"title": "Smolen JS. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): A randomised controlled trial. The Lancet. 2013;381(9870):918.", "paper_uid": "d783a7f7", "reference": "Smolen JS. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): A randomised controlled trial. The Lancet. 2013;381(9870):918.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "52", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "23332236"}
{"title": "Emery P. Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis. New England Journal of Medicine. 2014;371:1781-92.", "paper_uid": "0570bda2", "reference": "Emery P. Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis. New England Journal of Medicine. 2014;371:1781-92.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "52", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "25372086"}
{"title": "Weinblatt ME. A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. Arthritis & Rheumatology. 2017;69(10):1937.", "paper_uid": "506166f3", "reference": "Weinblatt ME. A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. Arthritis & Rheumatology. 2017;69(10):1937.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "52", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "28666080"}
{"title": "van Vollenhoven RF. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis BMJ. 2016;75:52-8.", "paper_uid": "60bbc82c", "reference": "van Vollenhoven RF. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis BMJ. 2016;75:52-8.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "52", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "25873634"}
{"title": "Strand V. The impact of rheumatoid arthritis on work and predictors of overall work impairment from three therapeutic scenarios. International Journal of Clinical Rheumatology. 2015;10(5):317.", "paper_uid": "48d24eba", "reference": "Strand V. The impact of rheumatoid arthritis on work and predictors of overall work impairment from three therapeutic scenarios. International Journal of Clinical Rheumatology. 2015;10(5):317.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "52", "Database": "2021 ACR RA", "characteristics": {}, "pmid": null}
{"title": "Wiland P, Dudler J, Veale D, Tahir H, Pedersen R, Bukowski J, et al. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis. Journal of Rheumatology. 2016;43(7):1268.", "paper_uid": "4e39bd02", "reference": "Wiland P, Dudler J, Veale D, Tahir H, Pedersen R, Bukowski J, et al. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis. Journal of Rheumatology. 2016;43(7):1268.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "52", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "27252426"}
{"title": "Smolen JS. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): A randomised controlled trial. The Lancet. 2013;381(9870):918.", "paper_uid": "d783a7f7", "reference": "Smolen JS. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): A randomised controlled trial. The Lancet. 2013;381(9870):918.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "52", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "23332236"}
{"title": "van Vollenhoven RF. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis BMJ. 2016;75:52-8.", "paper_uid": "60bbc82c", "reference": "van Vollenhoven RF. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis BMJ. 2016;75:52-8.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "52", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "25873634"}
{"title": "van Herwaarden N, van der Maas A, Minten MJ, van den Hoogen FH, Kievit W, van Vollenhoven RF, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: Open label, randomised controlled, non-inferiority trial. BMJ (Online). 2015;350(no pagination).", "paper_uid": "47043953", "reference": "van Herwaarden N, van der Maas A, Minten MJ, van den Hoogen FH, Kievit W, van Vollenhoven RF, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: Open label, randomised controlled, non-inferiority trial. BMJ (Online). 2015;350(no pagination).", "study_design": "Randomized Controlled Trial", "PICO_IDX": "52", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "25858265"}
{"title": "Strand V. The impact of rheumatoid arthritis on work and predictors of overall work impairment from three therapeutic scenarios. International Journal of Clinical Rheumatology. 2015;10(5):317.", "paper_uid": "48d24eba", "reference": "Strand V. The impact of rheumatoid arthritis on work and predictors of overall work impairment from three therapeutic scenarios. International Journal of Clinical Rheumatology. 2015;10(5):317.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "52", "Database": "2021 ACR RA", "characteristics": {}, "pmid": null}
{"title": "Emery P. Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis. New England Journal of Medicine. 2014;371:1781-92.", "paper_uid": "0570bda2", "reference": "Emery P. Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis. New England Journal of Medicine. 2014;371:1781-92.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "53", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "25372086"}
{"title": "Weinblatt ME. A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. Arthritis & Rheumatology. 2017;69(10):1937.", "paper_uid": "506166f3", "reference": "Weinblatt ME. A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. Arthritis & Rheumatology. 2017;69(10):1937.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "53", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "28666080"}
{"title": "Wiland P, Dudler J, Veale D, Tahir H, Pedersen R, Bukowski J, et al. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis. Journal of Rheumatology. 2016;43(7):1268.", "paper_uid": "4e39bd02", "reference": "Wiland P, Dudler J, Veale D, Tahir H, Pedersen R, Bukowski J, et al. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis. Journal of Rheumatology. 2016;43(7):1268.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "53", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "27252426"}
{"title": "Sanmarti R. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial. Arthritis & Rheumatism. 2019;71(10):1616-25.", "paper_uid": "331cb258", "reference": "Sanmarti R. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial. Arthritis & Rheumatism. 2019;71(10):1616-25.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "53", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "31087542"}
{"title": "Fautrel B, Pham T, Alfaiate T, Gandjbakhch F, Foltz V, Morel J, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: Results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases. 2016;75(1):59.", "paper_uid": "3ca3e366", "reference": "Fautrel B, Pham T, Alfaiate T, Gandjbakhch F, Foltz V, Morel J, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: Results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases. 2016;75(1):59.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "53", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "26103979"}
{"title": "Miedany Y. Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clin Rheumatol. 2016;35:2915–23.", "paper_uid": "a4d3750d", "reference": "Miedany Y. Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clin Rheumatol. 2016;35:2915–23.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "53", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "27658417"}
{"title": "Smolen JS. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): A randomised controlled trial. The Lancet. 2013;381(9870):918.", "paper_uid": "d783a7f7", "reference": "Smolen JS. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): A randomised controlled trial. The Lancet. 2013;381(9870):918.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "54a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "23332236"}
{"title": "Chatzidionysiou K. A multicentre, randomised, controlled,open-label pilot study on the feasibilityof discontinuation of adalimumab inestablished patients with rheumatoidarthritis in stable clinical remission. 2016;2.", "paper_uid": "04645c61", "reference": "Chatzidionysiou K. A multicentre, randomised, controlled,open-label pilot study on the feasibilityof discontinuation of adalimumab inestablished patients with rheumatoidarthritis in stable clinical remission. 2016;2.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "54a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "26819752"}
{"title": "van Herwaarden N, van der Maas A, Minten MJ, van den Hoogen FH, Kievit W, van Vollenhoven RF, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: Open label, randomised controlled, non-inferiority trial. BMJ (Online). 2015;350(no pagination).", "paper_uid": "47043953", "reference": "van Herwaarden N, van der Maas A, Minten MJ, van den Hoogen FH, Kievit W, van Vollenhoven RF, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: Open label, randomised controlled, non-inferiority trial. BMJ (Online). 2015;350(no pagination).", "study_design": "Randomized Controlled Trial", "PICO_IDX": "54a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "25858265"}
{"title": "Strand V. The impact of rheumatoid arthritis on work and predictors of overall work impairment from three therapeutic scenarios. International Journal of Clinical Rheumatology. 2015;10(5):317.", "paper_uid": "48d24eba", "reference": "Strand V. The impact of rheumatoid arthritis on work and predictors of overall work impairment from three therapeutic scenarios. International Journal of Clinical Rheumatology. 2015;10(5):317.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "54a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": null}
{"title": "Fautrel B, Pham T, Alfaiate T, Gandjbakhch F, Foltz V, Morel J, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: Results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases. 2016;75(1):59.", "paper_uid": "3ca3e366", "reference": "Fautrel B, Pham T, Alfaiate T, Gandjbakhch F, Foltz V, Morel J, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: Results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases. 2016;75(1):59.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "54b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "26103979"}
{"title": "van Vollenhoven RF. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis BMJ. 2016;75:52-8.", "paper_uid": "60bbc82c", "reference": "van Vollenhoven RF. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis BMJ. 2016;75:52-8.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "54b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "25873634"}
{"title": "Moghadam MG. Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity. ARTHRITIS & RHEUMATOLOGY. 2016;68(8):1810-7.", "paper_uid": "1ce3bb38", "reference": "Moghadam MG. Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity. ARTHRITIS & RHEUMATOLOGY. 2016;68(8):1810-7.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "54b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "26866428"}
{"title": "Harigai M. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Modern Rheumatology. 2012;22:814-22.", "paper_uid": "03c1b15a", "reference": "Harigai M. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Modern Rheumatology. 2012;22:814-22.", "study_design": "Observational Study", "PICO_IDX": "57", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "22270346"}
{"title": "Pablos JL. Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study. Clinical & Experimental Rheumatology. 2019;37:437-44.", "paper_uid": "fab0cce3", "reference": "Pablos JL. Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study. Clinical & Experimental Rheumatology. 2019;37:437-44.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "59", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "30299241"}
{"title": "Genovese MC, Bathon JM, Martin RW, Fleischmann RM, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis & Rheumatism. 2002;46(6):1443.", "paper_uid": "eafc116f", "reference": "Genovese MC, Bathon JM, Martin RW, Fleischmann RM, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis & Rheumatism. 2002;46(6):1443.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "5a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "12115173"}
{"title": "Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Vollenhoven Rv, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis & Rheumatism. 2006;54(1):26.", "paper_uid": "2140c6ee", "reference": "Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Vollenhoven Rv, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis & Rheumatism. 2006;54(1):26.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "5a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "16385520"}
{"title": "Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. American Journal of Managed Care. 2002;8(3):231.", "paper_uid": "1059324c", "reference": "Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. American Journal of Managed Care. 2002;8(3):231.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "5a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "11915973"}
{"title": "Burmester GR. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Annals of the Rheumatic Diseases. 2016;75(6):1081.", "paper_uid": "5fc10a78", "reference": "Burmester GR. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Annals of the Rheumatic Diseases. 2016;75(6):1081.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "5a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "26511996"}
{"title": "VIBEKE STRAND AMR, MARY A. CIFALDI, NAIJUN CHEN, SANJOY ROY, and DENNIS REVICKI. Health-related Quality of Life Outcomes of Adalimumab for Patients with Early Rheumatoid Arthritis: Results from a Randomized Multicenter Study. The Journal of Rheumatology. 2012;39(1):63-72.", "paper_uid": "c45ae481", "reference": "VIBEKE STRAND AMR, MARY A. CIFALDI, NAIJUN CHEN, SANJOY ROY, and DENNIS REVICKI. Health-related Quality of Life Outcomes of Adalimumab for Patients with Early Rheumatoid Arthritis: Results from a Randomized Multicenter Study. The Journal of Rheumatology. 2012;39(1):63-72.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "5a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "22045836"}
{"title": "Liu Y. Risk of breast cancer and total malignancies in rheumatoid arthritis patients undergoing TNF-alpha antagonist therapy: a meta-analysis of randomized control trials. Asian Pacific Journal of Cancer Prevention: Apjcp. 2014;15(8):3403.", "paper_uid": "2bf70fbf", "reference": "Liu Y. Risk of breast cancer and total malignancies in rheumatoid arthritis patients undergoing TNF-alpha antagonist therapy: a meta-analysis of randomized control trials. Asian Pacific Journal of Cancer Prevention: Apjcp. 2014;15(8):3403.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "5a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "24870729"}
{"title": "de La Forest Divonne M, Gottenberg JE, Salliot C. Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers. [Review]. Joint, Bone, Spine: Revue du Rhumatisme. 2017;84(2):133.", "paper_uid": "542001cd", "reference": "de La Forest Divonne M, Gottenberg JE, Salliot C. Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers. [Review]. Joint, Bone, Spine: Revue du Rhumatisme. 2017;84(2):133.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "5a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "27341745"}
{"title": "Emery P. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: Results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Annals of the Rheumatic Diseases. 2015;74(1):19.", "paper_uid": "2a7a858b", "reference": "Emery P. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: Results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Annals of the Rheumatic Diseases. 2015;74(1):19.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "5a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "25367713"}
{"title": "Maneiro JR. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. [Review]. Seminars in Arthritis & Rheumatism. 2017;47(2):149.", "paper_uid": "1fbf0f4e", "reference": "Maneiro JR. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. [Review]. Seminars in Arthritis & Rheumatism. 2017;47(2):149.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "5a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "28284845"}
{"title": "Burmester GR. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Annals of the Rheumatic Diseases. 2016;75(6):1081.", "paper_uid": "5fc10a78", "reference": "Burmester GR. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Annals of the Rheumatic Diseases. 2016;75(6):1081.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "5a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "26511996"}
{"title": "Lopez-Olivo MAT, J.H; Martinez-Lopez, J.A.; Pollono, E.N.; Cueto, J.P.; Gonzales-Crespo, M.R.; Fulton, S.; Suarez-Almazor, M.E. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898.", "paper_uid": "45b0286b", "reference": "Lopez-Olivo MAT, J.H; Martinez-Lopez, J.A.; Pollono, E.N.; Cueto, J.P.; Gonzales-Crespo, M.R.; Fulton, S.; Suarez-Almazor, M.E. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "5a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "22948700"}
{"title": "Geng Z. Tocilizumab and the risk of respiratory adverse events in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised controlled trials. [Review]. Clinical & Experimental Rheumatology.2018 Aug 29.", "paper_uid": "f1b7a867", "reference": "Geng Z. Tocilizumab and the risk of respiratory adverse events in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised controlled trials. [Review]. Clinical & Experimental Rheumatology.2018 Aug 29.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "5a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "30183597"}
{"title": "Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. New England Journal of Medicine. 2014;370(25):2377.", "paper_uid": "456cb129", "reference": "Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. New England Journal of Medicine. 2014;370(25):2377.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "5a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "24941177"}
{"title": "Maneiro JR. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. [Review]. Seminars in Arthritis & Rheumatism. 2017;47(2):149.", "paper_uid": "1fbf0f4e", "reference": "Maneiro JR. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. [Review]. Seminars in Arthritis & Rheumatism. 2017;47(2):149.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "5a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "28284845"}
{"title": "Genovese MC, Bathon JM, Martin RW, Fleischmann RM, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis & Rheumatism. 2002;46(6):1443.", "paper_uid": "eafc116f", "reference": "Genovese MC, Bathon JM, Martin RW, Fleischmann RM, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis & Rheumatism. 2002;46(6):1443.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "5b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "12115173"}
{"title": "Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Vollenhoven Rv, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis & Rheumatism. 2006;54(1):26.", "paper_uid": "2140c6ee", "reference": "Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Vollenhoven Rv, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis & Rheumatism. 2006;54(1):26.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "5b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "16385520"}
{"title": "Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. American Journal of Managed Care. 2002;8(3):231.", "paper_uid": "1059324c", "reference": "Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. American Journal of Managed Care. 2002;8(3):231.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "5b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "11915973"}
{"title": "VIBEKE STRAND AMR, MARY A. CIFALDI, NAIJUN CHEN, SANJOY ROY, and DENNIS REVICKI. Health-related Quality of Life Outcomes of Adalimumab for Patients with Early Rheumatoid Arthritis: Results from a Randomized Multicenter Study. The Journal of Rheumatology. 2012;39(1):63-72.", "paper_uid": "c45ae481", "reference": "VIBEKE STRAND AMR, MARY A. CIFALDI, NAIJUN CHEN, SANJOY ROY, and DENNIS REVICKI. Health-related Quality of Life Outcomes of Adalimumab for Patients with Early Rheumatoid Arthritis: Results from a Randomized Multicenter Study. The Journal of Rheumatology. 2012;39(1):63-72.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "5b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "22045836"}
{"title": "Liu Y. Risk of breast cancer and total malignancies in rheumatoid arthritis patients undergoing TNF-alpha antagonist therapy: a meta-analysis of randomized control trials. Asian Pacific Journal of Cancer Prevention: Apjcp. 2014;15(8):3403.", "paper_uid": "2bf70fbf", "reference": "Liu Y. Risk of breast cancer and total malignancies in rheumatoid arthritis patients undergoing TNF-alpha antagonist therapy: a meta-analysis of randomized control trials. Asian Pacific Journal of Cancer Prevention: Apjcp. 2014;15(8):3403.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "5b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "24870729"}
{"title": "de La Forest Divonne M, Gottenberg JE, Salliot C. Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers. [Review]. Joint, Bone, Spine: Revue du Rhumatisme. 2017;84(2):133.", "paper_uid": "542001cd", "reference": "de La Forest Divonne M, Gottenberg JE, Salliot C. Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers. [Review]. Joint, Bone, Spine: Revue du Rhumatisme. 2017;84(2):133.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "5b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "27341745"}
{"title": "Emery P. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: Results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Annals of the Rheumatic Diseases. 2015;74(1):19.", "paper_uid": "2a7a858b", "reference": "Emery P. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: Results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Annals of the Rheumatic Diseases. 2015;74(1):19.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "5b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "25367713"}
{"title": "Maneiro JR. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. [Review]. Seminars in Arthritis & Rheumatism. 2017;47(2):149.", "paper_uid": "1fbf0f4e", "reference": "Maneiro JR. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. [Review]. Seminars in Arthritis & Rheumatism. 2017;47(2):149.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "5b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "28284845"}
{"title": "Burmester GR. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Annals of the Rheumatic Diseases. 2016;75(6):1081.", "paper_uid": "5fc10a78", "reference": "Burmester GR. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Annals of the Rheumatic Diseases. 2016;75(6):1081.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "5b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "26511996"}
{"title": "Maneiro JR. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. [Review]. Seminars in Arthritis & Rheumatism. 2017;47(2):149.", "paper_uid": "1fbf0f4e", "reference": "Maneiro JR. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. [Review]. Seminars in Arthritis & Rheumatism. 2017;47(2):149.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "5b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "28284845"}
{"title": "Geng Z. Tocilizumab and the risk of respiratory adverse events in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised controlled trials. [Review]. Clinical & Experimental Rheumatology.2018 Aug 29.", "paper_uid": "f1b7a867", "reference": "Geng Z. Tocilizumab and the risk of respiratory adverse events in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised controlled trials. [Review]. Clinical & Experimental Rheumatology.2018 Aug 29.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "5b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "30183597"}
{"title": "Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. New England Journal of Medicine. 2014;370(25):2377.", "paper_uid": "456cb129", "reference": "Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. New England Journal of Medicine. 2014;370(25):2377.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "5b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "24941177"}
{"title": "Maneiro JR. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. [Review]. Seminars in Arthritis & Rheumatism. 2017;47(2):149.", "paper_uid": "1fbf0f4e", "reference": "Maneiro JR. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. [Review]. Seminars in Arthritis & Rheumatism. 2017;47(2):149.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "5b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "28284845"}
{"title": "Smolen JS. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): A randomised controlled trial. The Lancet. 2013;381(9870):918.", "paper_uid": "d783a7f7", "reference": "Smolen JS. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): A randomised controlled trial. The Lancet. 2013;381(9870):918.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "62", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "23332236"}
{"title": "Ibrahim F, Lorente-Canovas B, Dore CJ, Bosworth A, Ma MH, Galloway JB, et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders? Rheumatology. 2017;56(11):2004.", "paper_uid": "d2d2cd6c", "reference": "Ibrahim F, Lorente-Canovas B, Dore CJ, Bosworth A, Ma MH, Galloway JB, et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders? Rheumatology. 2017;56(11):2004.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "62", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "28968858"}
{"title": "van Vollenhoven RF. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis BMJ. 2016;75:52-8.", "paper_uid": "60bbc82c", "reference": "van Vollenhoven RF. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis BMJ. 2016;75:52-8.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "62", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "25873634"}
{"title": "Miedany Y. Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clin Rheumatol. 2016;35:2915–23.", "paper_uid": "a4d3750d", "reference": "Miedany Y. Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clin Rheumatol. 2016;35:2915–23.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "62", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "27658417"}
{"title": "Fautrel B, Pham T, Alfaiate T, Gandjbakhch F, Foltz V, Morel J, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: Results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases. 2016;75(1):59.", "paper_uid": "3ca3e366", "reference": "Fautrel B, Pham T, Alfaiate T, Gandjbakhch F, Foltz V, Morel J, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: Results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases. 2016;75(1):59.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "62", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "26103979"}
{"title": "van Herwaarden N, van der Maas A, Minten MJ, van den Hoogen FH, Kievit W, van Vollenhoven RF, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: Open label, randomised controlled, non-inferiority trial. BMJ (Online). 2015;350(no pagination).", "paper_uid": "47043953", "reference": "van Herwaarden N, van der Maas A, Minten MJ, van den Hoogen FH, Kievit W, van Vollenhoven RF, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: Open label, randomised controlled, non-inferiority trial. BMJ (Online). 2015;350(no pagination).", "study_design": "Randomized Controlled Trial", "PICO_IDX": "62", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "25858265"}
{"title": "Emery P. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Annals of the Rheumatic Diseases. 2017;76(1):96.", "paper_uid": "aa711738", "reference": "Emery P. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Annals of the Rheumatic Diseases. 2017;76(1):96.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "27165179"}
{"title": "Detert J. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Annals of the Rheumatic Diseases. 2013;72(6):844.", "paper_uid": "834e46fa", "reference": "Detert J. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Annals of the Rheumatic Diseases. 2013;72(6):844.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "22739990"}
{"title": "Nam JL, Villeneuve E, Hensor EM, Wakefield RJ, Conaghan PG, Green MJ, et al. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Annals of the Rheumatic Diseases. 2014;73(6):1027.", "paper_uid": "d354991c", "reference": "Nam JL, Villeneuve E, Hensor EM, Wakefield RJ, Conaghan PG, Green MJ, et al. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Annals of the Rheumatic Diseases. 2014;73(6):1027.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "24618266"}
{"title": "Lopez-Olivo MAT, J.H; Martinez-Lopez, J.A.; Pollono, E.N.; Cueto, J.P.; Gonzales-Crespo, M.R.; Fulton, S.; Suarez-Almazor, M.E. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898.", "paper_uid": "45b0286b", "reference": "Lopez-Olivo MAT, J.H; Martinez-Lopez, J.A.; Pollono, E.N.; Cueto, J.P.; Gonzales-Crespo, M.R.; Fulton, S.; Suarez-Almazor, M.E. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "6a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "22948700"}
{"title": "Westhovens Rea. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis BMJ. 2009;68(12):1870-7.", "paper_uid": "e4903996", "reference": "Westhovens Rea. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis BMJ. 2009;68(12):1870-7.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "19124524"}
{"title": "Emery P. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: Results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Annals of the Rheumatic Diseases. 2015;74(1):19.", "paper_uid": "2a7a858b", "reference": "Emery P. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: Results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Annals of the Rheumatic Diseases. 2015;74(1):19.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "25367713"}
{"title": "Lopez-Olivo MAT, J.H; Martinez-Lopez, J.A.; Pollono, E.N.; Cueto, J.P.; Gonzales-Crespo, M.R.; Fulton, S.; Suarez-Almazor, M.E. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898.", "paper_uid": "45b0286b", "reference": "Lopez-Olivo MAT, J.H; Martinez-Lopez, J.A.; Pollono, E.N.; Cueto, J.P.; Gonzales-Crespo, M.R.; Fulton, S.; Suarez-Almazor, M.E. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "6a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "22948700"}
{"title": "Tak PPea. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis BMJ. 2011;71(3):351-7.", "paper_uid": "2f031aec", "reference": "Tak PPea. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis BMJ. 2011;71(3):351-7.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "22012969"}
{"title": "Lopez-Olivo MAT, J.H; Martinez-Lopez, J.A.; Pollono, E.N.; Cueto, J.P.; Gonzales-Crespo, M.R.; Fulton, S.; Suarez-Almazor, M.E. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898.", "paper_uid": "45b0286b", "reference": "Lopez-Olivo MAT, J.H; Martinez-Lopez, J.A.; Pollono, E.N.; Cueto, J.P.; Gonzales-Crespo, M.R.; Fulton, S.; Suarez-Almazor, M.E. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "6a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "22948700"}
{"title": "Burmester GR. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Annals of the Rheumatic Diseases. 2016;75(6):1081.", "paper_uid": "5fc10a78", "reference": "Burmester GR. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Annals of the Rheumatic Diseases. 2016;75(6):1081.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "26511996"}
{"title": "Campbell LC, C.; Bhagat, S. S.; Parker, R. A.; Ostor, A. J. K. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford academic). 2010;50(3):552-62.", "paper_uid": "286647a1", "reference": "Campbell LC, C.; Bhagat, S. S.; Parker, R. A.; Ostor, A. J. K. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford academic). 2010;50(3):552-62.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "6a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "21078627"}
{"title": "Atsumi Tea. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis BMJ. 2016;75:75-83.", "paper_uid": "fbec7a1c", "reference": "Atsumi Tea. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis BMJ. 2016;75:75-83.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "26139005"}
{"title": "Kavanaugh A. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Annals of the Rheumatic Diseases. 2013;72(1):64.", "paper_uid": "07165ed3", "reference": "Kavanaugh A. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Annals of the Rheumatic Diseases. 2013;72(1):64.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "22562973"}
{"title": "Emery P. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis and Rheumatism. 2009;60(8):2272.", "paper_uid": "7ef8f3ac", "reference": "Emery P. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis and Rheumatism. 2009;60(8):2272.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "19644849"}
{"title": "Bejarano V. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Care and Research. 2008;59(10):1467.", "paper_uid": "7321b644", "reference": "Bejarano V. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Care and Research. 2008;59(10):1467.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "18821658"}
{"title": "Emery P. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372(9636):375.", "paper_uid": "54351bf3", "reference": "Emery P. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372(9636):375.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "18635256"}
{"title": "Durez P, Malghem J, Toukap AN, Depresseux G, Lauwerys BR, Westhovens R, et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis & Rheumatism. 2007;56(12):3919.", "paper_uid": "72824791", "reference": "Durez P, Malghem J, Toukap AN, Depresseux G, Lauwerys BR, Westhovens R, et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis & Rheumatism. 2007;56(12):3919.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "18050189"}
{"title": "Moreland LW, Zhang J. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The treatment of early aggressive rheumatoid arthritis trial. Arthritis and Rheumatism. 2012;64(9):2824.", "paper_uid": "ccd87125", "reference": "Moreland LW, Zhang J. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The treatment of early aggressive rheumatoid arthritis trial. Arthritis and Rheumatism. 2012;64(9):2824.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "22508468"}
{"title": "Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Vollenhoven Rv, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis & Rheumatism. 2006;54(1):26.", "paper_uid": "2140c6ee", "reference": "Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Vollenhoven Rv, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis & Rheumatism. 2006;54(1):26.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "16385520"}
{"title": "Clair EWS, Heijde DMvd, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis and Rheumatism. 2004;50(11):3432.", "paper_uid": "cbcb86ec", "reference": "Clair EWS, Heijde DMvd, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis and Rheumatism. 2004;50(11):3432.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "15529377"}
{"title": "VIBEKE STRAND AMR, MARY A. CIFALDI, NAIJUN CHEN, SANJOY ROY, and DENNIS REVICKI. Health-related Quality of Life Outcomes of Adalimumab for Patients with Early Rheumatoid Arthritis: Results from a Randomized Multicenter Study. The Journal of Rheumatology. 2012;39(1):63-72.", "paper_uid": "c45ae481", "reference": "VIBEKE STRAND AMR, MARY A. CIFALDI, NAIJUN CHEN, SANJOY ROY, and DENNIS REVICKI. Health-related Quality of Life Outcomes of Adalimumab for Patients with Early Rheumatoid Arthritis: Results from a Randomized Multicenter Study. The Journal of Rheumatology. 2012;39(1):63-72.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "22045836"}
{"title": "Kekow Jea. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis BMJ. 2010;69:222-5.", "paper_uid": "b6dac38c", "reference": "Kekow Jea. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis BMJ. 2010;69:222-5.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "19293160"}
{"title": "Emery Pea. Two-Year Clinical and Radiographic Results With Combination Etanercept–Methotrexate Therapy Versus Monotherapy in Early Rheumatoid Arthritis. ARTHRITIS & RHEUMATISM. 2010;62(3):674-82.", "paper_uid": "6a7646d3", "reference": "Emery Pea. Two-Year Clinical and Radiographic Results With Combination Etanercept–Methotrexate Therapy Versus Monotherapy in Early Rheumatoid Arthritis. ARTHRITIS & RHEUMATISM. 2010;62(3):674-82.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "20187135"}
{"title": "Lopez-Olivo MAT, J.H; Martinez-Lopez, J.A.; Pollono, E.N.; Cueto, J.P.; Gonzales-Crespo, M.R.; Fulton, S.; Suarez-Almazor, M.E. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898.", "paper_uid": "45b0286b", "reference": "Lopez-Olivo MAT, J.H; Martinez-Lopez, J.A.; Pollono, E.N.; Cueto, J.P.; Gonzales-Crespo, M.R.; Fulton, S.; Suarez-Almazor, M.E. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "6b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "22948700"}
{"title": "Westhovens Rea. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis BMJ. 2009;68(12):1870-7.", "paper_uid": "e4903996", "reference": "Westhovens Rea. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis BMJ. 2009;68(12):1870-7.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "19124524"}
{"title": "Emery P. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: Results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Annals of the Rheumatic Diseases. 2015;74(1):19.", "paper_uid": "2a7a858b", "reference": "Emery P. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: Results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Annals of the Rheumatic Diseases. 2015;74(1):19.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "25367713"}
{"title": "Lopez-Olivo MAT, J.H; Martinez-Lopez, J.A.; Pollono, E.N.; Cueto, J.P.; Gonzales-Crespo, M.R.; Fulton, S.; Suarez-Almazor, M.E. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898.", "paper_uid": "45b0286b", "reference": "Lopez-Olivo MAT, J.H; Martinez-Lopez, J.A.; Pollono, E.N.; Cueto, J.P.; Gonzales-Crespo, M.R.; Fulton, S.; Suarez-Almazor, M.E. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "6b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "22948700"}
{"title": "Tak PPea. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis BMJ. 2011;71(3):351-7.", "paper_uid": "2f031aec", "reference": "Tak PPea. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis BMJ. 2011;71(3):351-7.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "22012969"}
{"title": "RIGBY WF, G.; GREENWALD, M.; ZAZUETA-MONTIEL, B.; et. al. Effect of Rituximab on Physical Function and Quality of Life in Patients With Rheumatoid Arthritis Previously Untreated With Methotrexate. American College of Rheumatology. 2011;63(5):711-20.", "paper_uid": "9d737999", "reference": "RIGBY WF, G.; GREENWALD, M.; ZAZUETA-MONTIEL, B.; et. al. Effect of Rituximab on Physical Function and Quality of Life in Patients With Rheumatoid Arthritis Previously Untreated With Methotrexate. American College of Rheumatology. 2011;63(5):711-20.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "21557525"}
{"title": "Lopez-Olivo MAT, J.H; Martinez-Lopez, J.A.; Pollono, E.N.; Cueto, J.P.; Gonzales-Crespo, M.R.; Fulton, S.; Suarez-Almazor, M.E. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898.", "paper_uid": "45b0286b", "reference": "Lopez-Olivo MAT, J.H; Martinez-Lopez, J.A.; Pollono, E.N.; Cueto, J.P.; Gonzales-Crespo, M.R.; Fulton, S.; Suarez-Almazor, M.E. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "6b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "22948700"}
{"title": "Burmester GR. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Annals of the Rheumatic Diseases. 2016;75(6):1081.", "paper_uid": "5fc10a78", "reference": "Burmester GR. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Annals of the Rheumatic Diseases. 2016;75(6):1081.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "6b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "26511996"}
{"title": "Lopez-Olivo MAT, J.H; Martinez-Lopez, J.A.; Pollono, E.N.; Cueto, J.P.; Gonzales-Crespo, M.R.; Fulton, S.; Suarez-Almazor, M.E. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898.", "paper_uid": "45b0286b", "reference": "Lopez-Olivo MAT, J.H; Martinez-Lopez, J.A.; Pollono, E.N.; Cueto, J.P.; Gonzales-Crespo, M.R.; Fulton, S.; Suarez-Almazor, M.E. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898.", "study_design": "SYSTEMATIC_REVIEW", "PICO_IDX": "6b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "22948700"}
{"title": "Svensson B, Boonen A, Albertsson K, Heijde Dvd, Keller C, Hafstrom I. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis & Rheumatism. 2005;52(11):3360.", "paper_uid": "1b777329", "reference": "Svensson B, Boonen A, Albertsson K, Heijde Dvd, Keller C, Hafstrom I. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis & Rheumatism. 2005;52(11):3360.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "8a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "16255010"}
{"title": "Ajeganova S, Svensson B, Hafstrom I. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open. 2014;4(4).", "paper_uid": "1a7c95b6", "reference": "Ajeganova S, Svensson B, Hafstrom I. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open. 2014;4(4).", "study_design": "Randomized Controlled Trial", "PICO_IDX": "8a", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "24710131"}
{"title": "Capell HA, Madhok R, Hunter JA, Porter D, Morrison E, Larkin J, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Annals of the Rheumatic Diseases. 2004;63(7):797.", "paper_uid": "ac248aa9", "reference": "Capell HA, Madhok R, Hunter JA, Porter D, Morrison E, Larkin J, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Annals of the Rheumatic Diseases. 2004;63(7):797.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "8b", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "15194574"}
{"title": "Braun J. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis & Rheumatism. 2008;58(1):73.", "paper_uid": "5efdfbb8", "reference": "Braun J. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis & Rheumatism. 2008;58(1):73.", "study_design": "Randomized Controlled Trial", "PICO_IDX": "9", "Database": "2021 ACR RA", "characteristics": {}, "pmid": "18163521"}
